10-Q: AppYea Faces Going Concern Doubt Amidst Deep Losses

AppYea, Inc. reported significant financial challenges in its Q2 2025 filing, including recurring losses, negative cash flows, and a substantial accumulated deficit, raising doubts about its ability to continue as a going concern.

Summary

• AppYea, Inc. reported a net loss of $172,000 for the six months ended June 30, 2025, compared to a net loss of $1,063,000 for the same period in 2024.
• Revenues for the six months ended June 30, 2025, were $4,000, a significant decrease from $15,000 in the corresponding period of 2024.
• The company had cash and cash equivalents of $8,000 as of June 30, 2025, down from $79,000 at December 31, 2024.
• Total current liabilities increased to $4,312,000 as of June 30, 2025, from $1,666,000 at December 31, 2024, primarily due to long-term convertible loans becoming current.
• An accumulated deficit of $10,530,000 and a stockholders' deficiency of $4,160,000 were reported as of June 30, 2025.
• Management believes current funds will only last through October 2025 and requires additional operating capital.
• The company extended the maturity date of approximately $1.8 million in convertible notes to February 15, 2026, with interest frozen and a potential 10% premium upon cash repayment, contingent on raising additional capital.
• New CEO Yakir Abadi and Executive Chairman Eldar Edmond Grady were appointed effective August 12, 2025, and are set to receive substantial stock options (totaling 35% of fully diluted capital upon exercise) tied to performance and capital raise milestones.
• The company's disclosure controls and procedures were deemed not effective as of June 30, 2025, with a material weakness in segregation of duties.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by minimal revenue, significant losses, critically low cash reserves, and a 'going concern' warning. While management changes and debt extensions offer temporary relief, they are contingent on future capital raises, which will likely result in substantial shareholder dilution. The ineffective internal controls and ongoing legal issues add further negative sentiment.

Positives

• Net cash used in operating activities decreased to $213,000 for the six months ended June 30, 2025, from $442,000 in the prior year period.
• Operating loss decreased to $476,000 for the six months ended June 30, 2025, from $803,000 in the prior year period, primarily due to reduced sales and marketing and general and administrative expenses.
• The company successfully extended the maturity date of $1.8 million in convertible notes to February 15, 2026, providing short-term liquidity relief.
• New leadership, including a CEO and Executive Chairman, has been appointed, signaling a potential strategic shift and commitment to capital raising, with initial investments from entities controlled by the new executives totaling approximately $69,200.

Negatives

• Revenues significantly declined to $4,000 for the six months ended June 30, 2025, from $15,000 in the same period last year, indicating minimal product sales.
• The company reported a gross loss of $4,000 for the six months ended June 30, 2025, compared to a gross profit of $9,000 in the prior year period.
• Cash and cash equivalents plummeted to $8,000 as of June 30, 2025, from $79,000 at the end of 2024, highlighting severe liquidity constraints.
• Total current liabilities increased substantially to $4,312,000, and the company has an accumulated deficit of $10,530,000 and a stockholders' deficiency of $4,160,000.
• The company's ability to continue as a going concern is in substantial doubt due to recurring losses and dependence on external financing.
• Significant stock option grants to new management (totaling 35% of fully diluted capital upon exercise) and consultants could lead to substantial shareholder dilution.
• Disclosure controls and procedures were deemed ineffective, indicating weaknesses in financial reporting oversight.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and dependence on external financing.
• There is no assurance that the company will be successful in obtaining adequate financing needed for long-term research and development activities on commercially reasonable terms or at all.
• Insufficient liquidity resources may force the company to delay or reduce the scope of product development programs.
• The company is involved in a legal proceeding in Israel alleging breach of partnership and loan agreements, non-disclosure of transactions, and concealment of assets, which could have an adverse effect on the subsidiary SleepX and/or the company.
• A former CEO is alleging non-payment of amounts due under his employment agreement, which could lead to further legal action.
• The company's disclosure controls and procedures were not effective, and a material weakness in segregation of duties exists, raising risks of material misstatements in financial reporting.
• The company operates in the development stage with no significant revenues and no operating history, making future success highly uncertain.

Future Outlook

The company intends to focus on further development and commercialization of its products, subject to raising working capital. It plans to file a 510(k) FDA submission for the AppySleep LAB app for non-contact diagnosis of sleep apnea during 2026 and an FDA process for AppySleep PRO for sleep apnea treatment during 2027. The strategy includes expanding a diverse product pipeline, maintaining a global network of specialists, and establishing distribution channels through collaborative arrangements with healthcare providers and direct online sales. The company expects to incur substantial research and development expenses for the next several years and anticipates increased cash needs for operations. Management believes current funds will only last through October 2025 and requires additional capital to maintain operations and realize its business plan.

Management Comments

• "The Company is in the development stage with no significant revenues and no operating history."
• "To date, the Company has not generated any significant revenues, suffered recurring losses from operations, incurred negative cash flows from operating activities, and is dependent upon external sources for financing its operations."
• "The Company intends to continue to finance its operating activities by raising capital."
• "There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities on commercially reasonable terms or at all."
• "If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of its product candidates or may be required to implement cost reduction measures and may be required to delay part of its development programs."
• "Management believes that funds on hand, will enable us to fund our operations and capital expenditure requirements through October 2025."
• "We need to raise additional operating capital in order to maintain operations as presently conducted and to realize our business plan."
• "We cannot be sure that future funding will be available to us on acceptable terms, or at all. Due to often volatile nature of the financial markets, equity and debt financing may be difficult to obtain."

Industry Context

The company operates in the digital health sector, specifically targeting the anti-snoring and sleep apnea treatment markets. The global anti-snoring treatment market is projected to grow from $4.3 billion in 2020 to $8.6 billion by 2028 (9.07% CAGR), while the global sleep apnea device market is expected to reach $6.1 billion by 2028 (6.2% CAGR). North America currently dominates both markets. The company's focus on AI-based wearable solutions for at-home settings aligns with the broader industry trend towards accessible and accurate diagnostic and treatment tools, aiming to address issues of misdiagnosis and high costs. However, the company is in the early commercialization stage with minimal revenue, contrasting with established players in these growing markets.

Comparison to Industry Standards

• The company's minimal revenue of $4,000 for six months and significant accumulated deficit of $10.53 million are far below industry standards for established medical device or digital health companies, which typically generate substantial revenue streams and aim for profitability.
• The company's reliance on external financing and its 'going concern' warning indicate a financial instability not typical of mature or even rapidly growing industry peers who have achieved significant market penetration or secured substantial long-term funding.
• While the company's AppySleep product is in 'serial manufacturing and commercial stage,' its revenue figures suggest very limited market adoption compared to successful consumer health wearables or FDA-approved medical devices.
• The planned FDA submissions for AppySleep LAB (2026) and AppySleep PRO (2027) indicate a long pathway to full regulatory approval and widespread commercialization, a common challenge for early-stage medical technology companies, but the current financial state makes the successful completion of these milestones highly uncertain compared to well-funded competitors like ResMed or Philips, which have established product lines and regulatory approvals.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit filed on August 11, 2022, in Tel Aviv Magistrates Court (now District Court) against the Chairman, G.P.I.S Ltd., Nexsense, Inc., and SleepX, Ltd., alleging breach of partnership and loan agreements, non-disclosure of transactions, and concealment of assets (transfer of technology/patents to SleepX). Mediation efforts have failed, and the matter has been referred back to court.
• On April 10, 2025, the company received a letter from its former Chief Executive Officer alleging non-payment of amounts due under his employment agreement; no formal complaint has been filed as of the report date.

Related Party Transactions

• Short-term loans from related parties: SleepX borrowed $47,623 from Nexense Technologies USA. Inc. (majority owned by Chairman Boris Molchadsky) in 2021, bearing 5.02% annual interest in 2025. The minority shareholder of Ta-nooma advanced an interest-free loan of NIS 115,725 (approx. $34,319) to Ta-nooma in 2020.
• Related party payables: $57,000 as of June 30, 2025.
• Salaries and related costs, including stock-based compensation, to related parties amounted to $16,000 for the six months ended June 30, 2025 (compared to $445,000 in 2024), which includes amounts related to the former CEO who is no longer considered a related party as of January 19, 2025.
• Entities controlled by new CEO Yakir Abadi and Executive Chairman Eldar Grady invested 234,000 NIS (approx. $69,200) in the company in July 2025.
• The intercompany loan of approximately $2.4 million owed by SleepX to the company will be retired by way of the issuance of additional shares of SleepX ordinary shares to the company.
• 222,664 shares of Series A Preferred Stock held by Mr. Bary Molchadsky (Chairman's relative) are subject to conversion into 333,996,000 common shares, contingent on a share capital increase.

Stakeholder Impact

• Shareholders: Face significant dilution risk from substantial stock option grants to new management and consultants (35% of fully diluted capital upon exercise for new CEO/Chairman options alone) and potential future capital raises. The 'going concern' warning indicates a high risk of investment loss.
• Employees: Changes in management, including the termination of the former CFO's position, may impact employee morale and stability. The company's financial instability could affect job security.
• Creditors (Convertible Note Holders): While maturity dates for $1.8 million in convertible notes have been extended, repayment is contingent on the company raising additional operating capital, introducing uncertainty regarding timely repayment.
• Customers: The company's ability to continue product development and commercialization of AppySleep and future products (AppySleep LAB, AppySleep PRO) is at risk due to liquidity issues, potentially impacting product availability and support.
• Suppliers: The company's financial health and 'going concern' status could affect its ability to pay suppliers, potentially leading to disruptions in the supply chain for its products.

Next Steps

• Continue to finance operating activities by raising capital.
• Prepare for sales of the AppySleep product during the second quarter of 2025 (already passed, but mentioned as a plan).
• Begin final calibration for AppySleep LAB, followed by filing for 510(k) FDA approval during 2026.
• Continue development of AppySleep PRO and AppySleep LAB, followed by testing and preparation for FDA approval filing during 2027.
• Establish distribution channels through collaborative arrangements with major healthcare providers and consumer specialists.
• Sell products directly through the company's website and other online webstores worldwide.
• Engage with private insurance plans to develop reimbursement programs for product candidates.
• Vigorously defend against the ongoing lawsuit in Tel Aviv District Court.
• Address the material weakness in disclosure controls and procedures, particularly regarding segregation of duties.

Key Dates

Recommendation

The company is in a precarious financial position, explicitly stating 'substantial doubt' about its ability to continue as a going concern. It has minimal revenue, significant and growing accumulated losses, and critically low cash reserves that are projected to last only a few more months. While debt maturity extensions provide temporary relief, they are contingent on future capital raises, which will inevitably lead to massive shareholder dilution given the large option grants to new management (35% of fully diluted capital) and consultants. The ineffective internal controls and ongoing legal proceedings add further layers of risk and uncertainty. There is no clear path to profitability or sustainable operations without substantial, highly dilutive capital injections. This presents an extremely high risk for investors, making a 'strong sell' recommendation appropriate.

Keywords

Sleep Apnea, Snoring, Digital Health, Wearable Technology, Biofeedback, Medical Devices, FDA Approval, Going Concern, SEC Filing, 10-Q, APYP, Capital Raise, Liquidity, Financial Results